# A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT02735876** · PHASE3 · WITHDRAWN · sponsor: **Acerta Pharma BV**

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** acalabrutinib
- **DRUG:** ibrutinib
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT02735876
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-05
- **Primary completion:** 2020-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735876, "A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02735876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*